Endometrial Uterine Cancer—20-Year Comparative Mortality and Survival Analysis by Age, Race/Ethnicity, Stage, Grade, Disease Duration, Selected ICD-O-3 Histologic Oncophenotypes, and Cohort Entry Time Period: A Systematic Analysis of 155,218 Cases for Diagnosis Years 1975-2023
Abstract
This study encompasses a review of 155,218 cases from 1975 to 2023 using the National Cancer Institute’s Surveillance, Epidemiology, and End Results 8 Registry. Endometrial cancer is the most common gynecologic malignancy in the United States and accounts for 7% of all cancers in women. In 2026, the estimated number of new cases and deaths is 68,270 (3.2%) and 14,450 (2.3%), respectively. The observed age-adjusted rates of new cases/deaths per 100,000 in the Surveillance, Epidemiology, and End Results 8 Registry increased from 24.5 and 4.1, respectively, in 2000 to 29.2 and 5.6, respectively, in 2023, with 5-year relative survival decreasing from 86.7% in 2000 to an estimated 80.9% in 2016-2022. Approximately 3.1% of women will be diagnosed with uterine cancer at some point during their lifetime, based on data from 2021 to 2023. In 2023, there were an estimated 890,295 women living with uterine cancer in the United States. Risk factors for endometrial cancer include the following: estrogen-only hormone replacement therapy after menopause; tamoxifen to prevent or treat breast cancer; obesity; metabolic syndrome; type 2 diabetes; exposure of the endometrium to estrogen made by the body, such as that caused by nulliparity, early menarche, or late-onset menses; polyendocrine metabolic ovarian syndrome (old terminology: polycystic ovary syndrome); a first-degree family history of endometrial cancer (mother, sister, or daughter); genetic conditions such as Lynch syndrome; and endometrial hyperplasia.